At 31 December 2013
|
At 31 December 2012
|
||||||||||
Maximum
exposure
|
Offset
|
Exposure to
credit risk
(net)
|
Maximum
exposure
|
Offset
|
Exposure to
credit risk
(net)
|
||||||
US$m
|
US$m
|
US$m
|
US$m
|
US$m
|
US$m
|
||||||
Cash at bank and in hand:
|
|||||||||||
- balances with HSBC undertakings ..........
|
407
|
-
|
407
|
353
|
-
|
353
|
|||||
Derivatives ..................................................
|
2,789
|
(2,755)
|
34
|
3,768
|
(3,768)
|
-
|
|||||
Loans and advances to HSBC undertakings ..
|
53,344
|
-
|
53,344
|
41,675
|
-
|
41,675
|
|||||
Financial investments ..................................
|
1,210
|
-
|
1,210
|
1,208
|
-
|
1,208
|
|||||
Financial guarantees and similar contracts ...
|
52,836
|
-
|
52,836
|
49,402
|
-
|
49,402
|
|||||
Loan and other credit-related commitments
|
1,245
|
-
|
1,245
|
1,200
|
-
|
1,200
|
|||||
111,831
|
(2,755)
|
109,076
|
97,606
|
(3,768)
|
93,838
|
|
· asset-backed securities ('ABS's), including mortgage-backed securities ('MBS's) and related collateralised debt obligations ('CDO's);
|
|
· direct lending at fair value through profit or loss;
|
|
· monoline insurance companies ('monolines');
|
|
· leveraged finance transactions; and
|
|
· representations and warranties related to mortgage sales and securitisation activities.
|
A summary of the nature of HSBC's exposures is provided in the Appendix to Risk on page 274.
|
At 31 December 2013
|
At 31 December 2012
|
||||||
Carrying
amount29
|
Including
sub-prime
and Alt-A
|
Carrying
amount29
|
Including
sub-prime
and Alt-A
|
||||
US$bn
|
US$bn
|
US$bn
|
US$bn
|
||||
Asset-backed securities (ABSs)..................................
|
50.1
|
7.2
|
59.0
|
7.0
|
|||
- fair value through profit or loss .............................
|
3.1
|
0.2
|
3.4
|
0.2
|
|||
- available for sale30 .................................................
|
42.7
|
6.5
|
49.6
|
6.1
|
|||
- held to maturity30 .................................................
|
1.1
|
-
|
1.6
|
0.1
|
|||
- loans and receivables .............................................
|
3.2
|
0.5
|
4.4
|
0.6
|
|||
Direct lending at fair value through profit or loss .....
|
0.1
|
0.1
|
1.0
|
0.6
|
|||
Total ABSs and direct lending at fair value
through profit or loss ...........................................
|
50.2
|
7.3
|
60.0
|
7.6
|
|||
Less securities subject to risk mitigation from credit derivatives
with monolines and other financial institutions ....
|
(1.5)
|
(0.2)
|
(1.9)
|
(0.2)
|
|||
48.7
|
7.1
|
58.1
|
7.4
|
||||
Leveraged finance loans ...........................................
|
1.4
|
-
|
2.8
|
-
|
|||
- loans and receivables .............................................
|
1.4
|
-
|
2.8
|
-
|
|||
50.1
|
7.1
|
60.9
|
7.4
|
||||
Exposure including securities mitigated by credit derivatives with monolines and other financial institutions............................................................
|
51.6
|
7.3
|
62.8
|
7.6
|
2013
|
2012
|
||||||||||
Directly
held/Solitaire31
|
SEs
|
Total
|
Directly
held/Solitaire31
|
SEs
|
Total
|
||||||
US$m
|
US$m
|
US$m
|
US$m
|
US$m
|
US$m
|
||||||
Available-for-sale reserve at 1 January ........
|
(1,473)
|
(720)
|
(2,193)
|
(3,085)
|
(2,061)
|
(5,146)
|
|||||
Increase/(decrease) in fair value of securities
|
(442)
|
599
|
157
|
1,195
|
914
|
2,109
|
|||||
Effect of impairments32 ..............................
|
101
|
61
|
162
|
339
|
394
|
733
|
|||||
Repayment of capital ..................................
|
38
|
85
|
123
|
164
|
174
|
338
|
|||||
Other movements .......................................
|
262
|
(154)
|
108
|
(86)
|
(141)
|
(227)
|
|||||
Available-for-sale reserve at 31 December ...
|
(1,514)
|
(129)
|
(1,643)
|
(1,473)
|
(720)
|
(2,193)
|
For footnotes, see page 263.
|
2013
|
2012
|
||
US$m
|
US$m
|
||
Available-for-sale reserve .............................................................................................................
|
(37)
|
(787)
|
|
- related to asset-backed securities ...........................................................................................
|
(129)
|
(720)
|
|
Economic first loss protection .....................................................................................................
|
2,286
|
2,286
|
|
Carrying amount of capital notes liability ....................................................................................
|
457
|
249
|
|
Impairment (write-backs)/charge for the year:
|
|||
- allocated to HSBC ................................................................................................................
|
(20)
|
119
|
|
- allocated to capital note holders ...........................................................................................
|
(96)
|
-
|
A summary of our impairment methodologies is provided in the Appendix to Risk on page 272.
|
Year ended 31 December 2013
|
Year ended 31 December 2012
|
||||||||||
Directly
held/Solitaire31
|
SEs
|
Total
|
Directly
held/Solitaire31
|
SEs
|
Total
|
||||||
US$m
|
US$m
|
US$m
|
US$m
|
US$m
|
US$m
|
||||||
Sub-prime residential ...............
|
(16)
|
(100)
|
(116)
|
23
|
(67)
|
(44)
|
|||||
US Alt-A residential ................
|
(156)
|
(20)
|
(176)
|
(209)
|
190
|
(19)
|
|||||
Commercial property ..............
|
10
|
6
|
16
|
125
|
-
|
125
|
|||||
Other assets .............................
|
(11)
|
(2)
|
(13)
|
74
|
(4)
|
70
|
|||||
Total impairment charge/(write-back) ..............
|
(173)
|
(116)
|
(289)
|
13
|
119
|
132
|
|
For footnote, see page 263.
|
Trading
|
Available for sale
|
Held to maturity
|
Designated
at fair value through
profit or loss
|
Loans and receivables
|
Total
|
Of which
held through consolidated
SEs
|
Gross
principal
exposure33
|
Credit
default
swap
protection34
|
Net
principal
exposure35
|
||||||||||
US$m
|
US$m
|
US$m
|
US$m
|
US$m
|
US$m
|
US$m
|
US$m
|
US$m
|
US$m
|
||||||||||
At 31 December 2013
|
|||||||||||||||||||
Mortgage-related assets:
|
|||||||||||||||||||
Sub-prime residential ...........................
|
178
|
2,977
|
-
|
-
|
403
|
3,558
|
2,782
|
4,504
|
112
|
4,392
|
|||||||||
Direct lending .................................
|
46
|
-
|
-
|
-
|
-
|
46
|
-
|
106
|
-
|
106
|
|||||||||
MBSs and MBS CDOs .....................
|
132
|
2,977
|
-
|
403
|
3,512
|
2,782
|
4,398
|
112
|
4,286
|
||||||||||
US Alt-A residential ............................
|
101
|
3,538
|
18
|
-
|
134
|
3,791
|
2,926
|
5,692
|
100
|
5,592
|
|||||||||
Direct lending .................................
|
10
|
-
|
-
|
-
|
10
|
-
|
14
|
-
|
14
|
||||||||||
MBSs ..............................................
|
91
|
3,538
|
18
|
-
|
134
|
3,781
|
2,926
|
5,678
|
100
|
5,578
|
|||||||||
US Government agency and sponsored enterprises:
|
|||||||||||||||||||
MBSs ..............................................
|
178
|
18,661
|
1,110
|
-
|
-
|
19,949
|
-
|
19,812
|
-
|
19,812
|
|||||||||
Other residential .................................
|
618
|
1,925
|
-
|
-
|
399
|
2,942
|
1,513
|
3,981
|
53
|
3,928
|
|||||||||
Direct lending .................................
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
|||||||||
MBSs ..............................................
|
618
|
1,925
|
-
|
-
|
399
|
2,942
|
1,513
|
3,981
|
53
|
3,928
|
|||||||||
Commercial property
|
|||||||||||||||||||
MBSs and MBS CDOs .....................
|
133
|
5,667
|
-
|
104
|
669
|
6,573
|
5,146
|
7,188
|
-
|
7,188
|
|||||||||
1,208
|
32,768
|
1,128
|
104
|
1,605
|
36,813
|
12,367
|
41,177
|
265
|
40,912
|
||||||||||
Leveraged finance-related assets:
|
|||||||||||||||||||
ABSs and ABS CDOs ...........................
|
294
|
5,011
|
-
|
-
|
251
|
5,556
|
4,310
|
5,841
|
365
|
5,476
|
|||||||||
Student loan-related assets:
|
|||||||||||||||||||
ABSs and ABS CDOs ...........................
|
196
|
3,705
|
-
|
-
|
121
|
4,022
|
3,495
|
4,897
|
199
|
4,698
|
|||||||||
Other assets:
|
|||||||||||||||||||
ABSs and ABS CDOs ...........................
|
1,271
|
1,265
|
-
|
34
|
1,186
|
3,756
|
989
|
4,805
|
1,010
|
3,795
|
|||||||||
2,969
|
42,749
|
1,128
|
138
|
3,163
|
50,147
|
21,161
|
56,720
|
1,839
|
54,881
|
Trading
|
Available for sale
|
Held to maturity
|
Designated
at fair value through
profit or loss
|
Loans and receivables
|
Total
|
Of which
held through consolidated
SEs
|
Gross
principal
exposure33
|
Credit
default
swap
protection34
|
Net
principal
exposure35
|
||||||||||
US$m
|
US$m
|
US$m
|
US$m
|
US$m
|
US$m
|
US$m
|
US$m
|
US$m
|
US$m
|
||||||||||
At 31 December 2012
|
|||||||||||||||||||
Mortgage-related assets:
|
|||||||||||||||||||
Sub-prime residential ...........................
|
698
|
2,455
|
-
|
-
|
435
|
3,588
|
2,723
|
5,483
|
130
|
5,353
|
|||||||||
Direct lending .................................
|
566
|
-
|
-
|
-
|
-
|
566
|
482
|
1,221
|
-
|
1,221
|
|||||||||
MBSs and MBS CDOs .....................
|
132
|
2,455
|
-
|
-
|
435
|
3,022
|
2,241
|
4,262
|
130
|
4,132
|
|||||||||
US Alt-A residential ............................
|
157
|
3,658
|
118
|
-
|
157
|
4,090
|
2,994
|
6,992
|
100
|
6,892
|
|||||||||
Direct lending .................................
|
71
|
-
|
-
|
-
|
-
|
71
|
-
|
77
|
-
|
77
|
|||||||||
MBSs ..............................................
|
86
|
3,658
|
118
|
-
|
157
|
4,019
|
2,994
|
6,915
|
100
|
6,815
|
|||||||||
US Government agency and sponsored enterprises:
|
|||||||||||||||||||
MBSs ..............................................
|
369
|
23,341
|
1,455
|
-
|
-
|
25,165
|
-
|
23,438
|
-
|
23,438
|
|||||||||
Other residential .................................
|
695
|
2,084
|
-
|
-
|
499
|
3,278
|
1,459
|
3,888
|
87
|
3,801
|
|||||||||
Direct lending .................................
|
322
|
-
|
-
|
-
|
-
|
322
|
-
|
322
|
-
|
322
|
|||||||||
MBSs ..............................................
|
373
|
2,084
|
-
|
-
|
499
|
2,956
|
1,459
|
3,566
|
87
|
3,479
|
|||||||||
Commercial property
|
|||||||||||||||||||
MBSs and MBS CDOs .....................
|
164
|
6,995
|
-
|
109
|
1,319
|
8,587
|
5,959
|
9,489
|
-
|
9,489
|
|||||||||
2,083
|
38,533
|
1,573
|
109
|
2,410
|
44,708
|
13,135
|
49,290
|
317
|
48,973
|
||||||||||
Leveraged finance-related assets:
|
|||||||||||||||||||
ABSs and ABS CDOs ...........................
|
450
|
5,330
|
-
|
-
|
284
|
6,064
|
4,303
|
6,726
|
717
|
6,009
|
|||||||||
Student loan-related assets:
|
|||||||||||||||||||
ABSs and ABS CDOs ...........................
|
179
|
4,219
|
-
|
-
|
156
|
4,554
|
3,722
|
5,826
|
199
|
5,627
|
|||||||||
Other assets:
|
|||||||||||||||||||
ABSs and ABS CDOs ...........................
|
1,511
|
1,553
|
-
|
49
|
1,537
|
4,650
|
1,140
|
5,769
|
1,318
|
4,451
|
|||||||||
4,223
|
49,635
|
1,573
|
158
|
4,387
|
59,976
|
22,300
|
67,611
|
2,551
|
65,060
|
|
For footnotes, see page 263.
|
|
The above table excludes leveraged finance transactions, which are shown separately on page 209.
|
Notional
amount
|
Net exposure
before credit
valuation
adjustment
|
Credit
valuation
adjustment36
|
Net exposure
after credit
valuation
adjustment
|
||||
US$m
|
US$m
|
US$m
|
US$m
|
||||
At 31 December 2013
|
|||||||
Derivative transactions with monoline counterparties
|
|||||||
Monolines - investment grade (BBB- or above) .....
|
3,297
|
299
|
(61)
|
238
|
|||
Monolines - sub-investment grade (below BBB-) ....
|
523
|
190
|
(110)
|
80
|
|||
3,820
|
489
|
(171)
|
318
|
||||
At 31 December 2012
|
|||||||
Derivative transactions with monoline counterparties
|
|||||||
Monolines - investment grade (BBB- or above) .....
|
4,191
|
606
|
(121)
|
485
|
|||
Monolines - sub-investment grade (below BBB-) ....
|
957
|
303
|
(158)
|
145
|
|||
5,148
|
909
|
(279)
|
630
|
|
For footnotes, see page 263.
|
Exposures at 31 December 2013
|
Exposures at 31 December 2012
|
||||||||||
Funded37
|
Unfunded38
|
Total
|
Funded37
|
Unfunded38
|
Total
|
||||||
US$m
|
US$m
|
US$m
|
US$m
|
US$m
|
US$m
|
||||||
Europe ..........................................
|
1,256
|
176
|
1,432
|
2,108
|
162
|
2,270
|
|||||
North America ..............................
|
-
|
-
|
-
|
414
|
92
|
506
|
|||||
1,256
|
176
|
1,432
|
2,522
|
254
|
2,776
|
||||||
Held within:
|
|||||||||||
- loans and receivables ...............
|
1,256
|
176
|
1,432
|
2,522
|
252
|
2,774
|
|||||
- fair value through profit or loss ...............................................
|
-
|
-
|
-
|
-
|
2
|
2
|
|
· the purchase of US$24bn of third-party originated mortgages by HSBC Bank USA and their securitisation by HSBC Securities (USA) Inc. ('HSI') between 2005 and 2007;
|
|
· HSI acting as underwriter for the third-party issuance of private label MBSs with an original issuance value of US$37bn, most of which were sub-prime; and
|
|
· the origination and sale by HSBC Bank USA of mortgage loans, primarily to government-sponsored entities.
|